Document:

First Amended and Restated License Agreement

 Exhibit 10.24(a) 
 FIRST AMENDED AND RESTATED LICENSE AGREEMENT 
 This First Amended and Restated License Agreement (the
“Agreement”) is entered into and effective as of September 12, 2007 (the “Effective Date”), by and between Helix BioMedix, Inc. a Delaware corporation with its principal place of business at 22118 20th Avenue
SE, Suite 204, Bothell, WA 98021 (“Licensor”), and Grant Industries, Inc. a New Jersey corporation with its principal place of business at 103 Main Avenue, Elmwood Park, NJ 07407 (“Licensee”). Licensor and Licensee
each may be referred to in this Agreement individually as a “Party” or collectively as the “Parties.” 
 RECITALS 
 A. The Parties entered into a Non-Exclusive License Agreement effective December 12, 2006 (the “Prior
Agreement”). 
 B. The Parties entered into a First Amendment to License Agreement effective May 2, 2007 (the “First
Amendment”), which amended Sections 3.1 and 4.1 of the Prior Agreement, concerning, respectively, royalty payment schedules and certain progress reports. 
 C. The Parties now wish to amend and restate the Prior Agreement in its entirety to, among other things, render the license herein exclusive with respect to a certain Peptide, to add an additional Peptide to the
exclusive license hereunder, and to incorporate the amendments set forth in the First Amendment. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do agree as follows: 
 This Agreement is effective
as of the Effective Date and amends, restates, and supersedes in its entirety the Prior Agreement, as amended by the First Amendment. This Agreement shall not impair or otherwise affect any right or obligation of either Party existing under the
Prior Agreement (as amended) prior to the effectiveness hereof. 
 1 – DEFINITIONS 
 For the purposes of this Agreement, the following words and phrases shall have the following meanings: 
 1.1 “Affiliate” means any entity that directly or indirectly through one or more intermediaries, controls, is controlled by or is under
common control with another entity. For purposes of this definition only, “control”, and, with correlative meanings, the terms “controlled 

  

  

 Confidential treatment has been requested for portions of this exhibit. This exhibit omits the information subject to the confidential treatment request. Omissions are designated as ***. A complete version of this
exhibit has been filed separately with the Securities and Exchange Commission. 

 
by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to direct the management or
policies of a party, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership, directly or indirectly, of more than twenty-five percent (25%) of the voting
securities or other ownership interest of a party; provided that, if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by
foreign interests. 
 1.2 “Applicable Law” means the applicable laws, rules, and regulations, including any rules,
regulations, guidelines, or other requirements of the Regulatory Authorities, that may be in effect from time to time in the Territory. 
 1.3 “Confidential Information” means the terms and conditions of this Agreement, all non-public information related to the Peptides, all Know-How, and all other information, data, reports and other records that a Party to
this Agreement receives from the other Party to this Agreement. 
 1.4 “GAAP” means United States generally accepted
accounting principles consistently applied. 
 1.5 “Know-How” means trade secrets, knowledge, information, expertise, data,
materials and know-how that are owned, have been developed and/or created or are developed during the term of this Agreement by or for the Licensor related to the research, development, use or manufacture of the Peptides. 
 1.6 “Market” means the cosmetic- and over-the-counter- personal-care products market. 
 1.7 “Net Revenue” means *** 
 1.8 “Patents” means the patents and patent applications set forth in Exhibit A. 
 1.9
“Peptides” means Licensor’s proprietary bioactive peptides described in Exhibit A attached to this Agreement. Licensor may add peptides that are proprietary to Licensor to Exhibit A at its sole discretion.

 1.10 “Peptide A”, “Peptide B” and “Peptide C” have the meanings given in Exhibit
A. 
 1.11 “Premix” means a formulation other than a final formulation that is manufactured by Licensee and that
incorporates any single Peptide (as defined above), regardless of what ingredients (of Licensee or any third party) other than Peptide may be included in such formulation. 
 1.12 “Regulatory Authorities” means any applicable governmental entities regulating or otherwise exercising authority in the Territory.

  

	***	Confidential treatment requested 

 2 

 1.13 “Royalties” means the royalties payable by Licensee set forth in Exhibit C,
which shall be paid in accordance with Section 3. 
 1.14 “Sublicensee” means any third party to which rights hereunder
are sublicensed in accordance with Section 2.2 (including any further sublicensees of a sublicensee). 
 1.15
“Territory” means the countries or other geographic areas set forth in Exhibit B, as such exhibit may be amended from time to time pursuant to the terms hereof. 
 2 – LICENSE GRANT 
 2.1 License. Subject to the terms and conditions of
this Agreement, Licensor hereby grants to Licensee a right and license, under the Patents and the Know-How, to (i) purchase the Peptides in pure form, at Licensee’s expense, from a manufacturer approved in advance by Licensor in writing
(or from Licensor, subject to availability and on terms as may be agreed between Licensee and Licensor); (ii) formulate the Peptides into Premix; provided that no Premix may contain more than one Peptide; and (iii) market, sell and
distribute the Premix to manufacturers in the Market in accordance with Section 2.2, in each case in the Territory and for commercial purposes only. The licenses granted herein shall be non-exclusive with respect to Peptide A, and Licensee
acknowledges and agrees that Licensor intends to grant the same or similar rights to other parties. The licenses granted herein with respect to Peptide B and Peptide C shall be exclusive (including as against Licensor) with respect to the rights
granted in Section 2.1(ii) and (iii). 
 2.2 Sublicense. Subject to the terms and conditions of this Agreement, Licensee may
grant rights to third parties that purchase Premix from Licensee to (i) market, sell and distribute such Premix to manufacturers in the Market and (ii) incorporate such Premix into final products within the Market and market, sell and
distribute such final products, in each case in the Territory and for commercial purposes only. Licensee shall notify Licensor of the identity of each Sublicensee promptly after any sublicense of rights is made hereunder. Licensee shall recommend in
writing to each Sublicensee that Peptide (considered in pure form) be present in any final formulation at a concentration level not less than those set forth in Exhibit A with respect to each Peptide, and as agreed between the Parties with
respect to any Peptide that may be added to Exhibit A pursuant to Section 1.9. Further, Licensee shall use its best efforts to prevent any use, sale, marketing or distribution of Premix or any product containing Premix by any third party
in a manner inconsistent with the terms or intent of this Agreement, and failing such prevention, to promptly notify Licensor of any such inconsistent use, sale, marketing or distribution by a third party. 
 2.3 No Other Rights. Except as expressly set forth in this Agreement, Licensor shall retain all right, title and interest in and to the Patents,
the Peptides and all Know-How, and nothing in this Agreement shall be construed to confer any rights upon Licensee by implication, estoppel or otherwise other than as expressly set forth in this Agreement. 
 2.4 Modification of Territory. Exhibit B may be amended from time to time upon request by Licensee and with the consent of Licensor, which
consent shall not be unreasonably 

  

	***	Confidential treatment requested 

 3 

 
withheld. Without limiting the generality of the foregoing, Licensor’s withholding of consent shall be deemed reasonable as to a country or geographic
region if at the time of the request by Licensee, Licensor is or is considering doing business (directly or indirectly) with respect to such country or geographic region, which business involves or may involve any Peptide. 
 2.5 No Assignment of Improvements. For avoidance of doubt, Licensee does not assign or otherwise transfer to Licensor hereunder any right,
title or interest in or to any improvements or inventions relating to, based upon, or derived from the Peptides that may be made by Licensee in connection with its performance under this Agreement. 
 3 – PAYMENTS 
 3.1 Royalties.
Royalties will be paid within thirty (30) days after the end of each three-month period ending the last day of February, May, August, and November during the term of this Agreement, with respect to royalty-bearing sales occurring in that
three-month period. Such payment will be accompanied by a statement with information set forth in Exhibit D indicating the associated Net Revenue (including currency conversions) itemized by Premix (including quantity sold), Royalties
payable, and the concentration of Peptide(s) in each Premix. At Licensor’s request, Licensee will also provide to Licensor records of Licensee that fairly reflect the Net Revenue attributable to a particular three-month period. 
 3.2 Minimum Royalties. Licensee agrees to comply with the minimum Royalty payment obligations set forth in Exhibit C hereto during the term
of this Agreement. 
 3.3 Payment Method. All amounts payable by Licensee to Licensor pursuant to this Agreement shall be paid in U.S.
dollars by wire transfer in immediately available funds to an account designated by Licensor. Any payments or portions thereof due hereunder which are not paid on the date such payments are due under this Agreement shall bear interest at a rate
equal to the lesser of (i) the prime rate as published in The Wall Street Journal, Western Edition, on the first day of each calendar month in which such payments are overdue, plus seven percentage points, or if less, (ii) the maximum rate
permitted by law, calculated on the number of days such payment is delinquent, compounded monthly. 
 4 – REPORTS 
 4.1 Progress Reports. Each calendar quarter during the term, the Parties shall discuss via teleconference or other agreed-upon means the progress
of the Agreement, in connection with which Licensee shall (a) describe any commercialization activities with respect to the Peptides and any other work relating to the Peptides that it has performed, or caused to be performed, since the last
such report, (b) evaluate the work performed in relation to the goals of this Agreement and Licensee’s work plans and (c) provide such other information as may be required by this Agreement or reasonably requested by Licensor relating
to such activities. 
  

	***	Confidential treatment requested 

 4 

 4.2 Record Retention. Licensee shall maintain complete and accurate books, records and accounts
that fairly reflect Peptide concentrations and quantities sold by customer in sufficient detail and in accordance with GAAP to confirm Licensee’s compliance with the terms and conditions of this Agreement and the accuracy of any payments
required hereunder, which books, records and accounts shall be retained by Licensee until the later of (i) three (3) years after the end of the period to which such books, records and accounts pertain and (ii) such longer period as
may be required under Applicable Law. 
 4.3 Audit. Licensor shall have the right to have an independent certified public accounting
firm of nationally recognized standing, reasonably acceptable to Licensee, have access during normal business hours, and upon reasonable prior written notice, to such records of the Licensee as may be reasonably necessary to verify compliance by
Licensee with the terms and conditions of this Agreement and the accuracy of any payments required hereunder for any three-month period described in Section 3.1 ending not more than forty-eight (48) months prior to the date of such
request; provided, however, that Licensor shall not have the right to conduct more than one such audit in any twelve (12)-month period. Licensor shall bear the cost of such audit unless the audit reveals a variance in any payments required hereunder
of more than 5%, in which case Licensee shall bear the cost of the audit. 
 4.4 Payment of Additional Amounts. If, based on the
results of an audit, additional payments are owed by Licensee, it shall make such additional payments, with interest from the date originally due at the rate of 1% per month, within thirty (30) days after the date on which the accounting
firm’s written report is delivered to Licensee. 
 4.5 Confidentiality. Licensor shall treat all information subject to review
under this Section 4 in accordance with the confidentiality provisions of Section 6 of this Agreement. 
 5 – INFRINGEMENT

 5.1 Infringement. In the event that Licensee learns of (i) any infringement of any of the Patents or (ii) any
misappropriation of any of the Know-How, Licensee shall promptly inform Licensor in writing and Licensor may elect to initiate and prosecute legal proceedings with respect thereto at Licensor’s cost and expense. In the event that Licensor
elects not to pursue such legal proceedings, Licensee shall have the right to do so at Licensee’s cost and expense. 
 5.2
Cooperation. In any infringement suit instituted by Licensor or Licensee pursuant to this Agreement, Licensor or Licensee as the case may be shall, at the other Party’s request and expense, cooperate in all reasonable respects and, to
the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens and the like. 
  

	***	Confidential treatment requested 

 5 

 6 – CONFIDENTIAL INFORMATION 
 6.1 Confidential Information. Each Party (“Receiving Party”) shall treat the terms and conditions of this Agreement and all of
the Confidential Information that it receives from the other Party (“Disclosing Party”) as secret, confidential, and proprietary of the Disclosing Party and shall not disclose or use such Confidential Information of the Disclosing
Party without the prior written consent of the Disclosing Party for any purpose except as expressly permitted under this Agreement. The Receiving Party shall develop and implement such procedures as may be required to prevent the intentional or
negligent disclosure to third parties of such Confidential Information of the Disclosing Party, including, but not limited to, requiring each of its employees having access to Confidential Information of the Disclosing Party to enter into a
proprietary information agreement consistent with, and no less protective of the Disclosing Party’s rights in the Confidential Information than, the terms set forth in this Section 6 and in this Agreement. Notwithstanding the foregoing,
each Party shall have the right to disclose Confidential Information as required by law (using reasonable best efforts to redact, where permitted by law), and to its auditors, accountants, potential investors and potential acquirers under
appropriate non-disclosure agreements. 
 6.2 Exclusions. Notwithstanding the foregoing, nothing in this Agreement shall prevent the
disclosure or use by the Receiving Party of the Disclosing Party’s Confidential Information that: 
 (a) prior to the transmittal thereof to the
Receiving Party was of general public knowledge; 
 (b) becomes, subsequent to the time of transmittal to the Receiving Party, a matter of general public
knowledge otherwise than as a consequence of a breach by the Receiving Party of any obligation under this Agreement; 
 (c) is made public by the Disclosing
Party; 
 (d) was in the possession of the Receiving Party in documentary form prior to the time of disclosure thereof to the Receiving Party by the
Disclosing Party, and is held by the Receiving Party free of any obligation of confidence to the Disclosing Party or any third party; or 
 (e) is received in
good faith from a third party having the right to disclose it, who did not obtain such Confidential Information from the Disclosing Party and who imposes no obligation of secrecy on the Receiving Party with respect to such Confidential Information.

 7 – REPRESENTATIONS AND WARRANTIES 
 7.1 Representations and Warranties of Licensor. Licensor represents and warrants that: (i) there are no actions or claims pending, nor to the best of its knowledge, threatened, against Licensor alleging
infringement of any patent, copyright, trademark or other intellectual property right relative to the Peptides; (ii) the grant of rights and licenses by Licensor to Licensee under this Agreement is not inconsistent with the terms and conditions
of any obligations of Licensor; (iii) no authorization or consent is required for Licensor to grant the rights and licenses under this Agreement or for Licensor to enter into this Agreement; and (iv) Licensor is duly organized and in good
standing in its state of incorporation. 
  

	***	Confidential treatment requested 

 6 

 7.2 Representations and Warranties of Licensee. Licensee represents and warrants that:
(i) the grant of rights and licenses by Licensee to Licensor under this Agreement is not inconsistent with the terms and conditions of any obligations of Licensee; (ii) no authorization or consent is required for Licensee to grant the
rights and licenses under this Agreement or for Licensee to enter into this Agreement; and (iii) Licensee is duly organized and in good standing in its state of incorporation. 
 8 – DISCLAIMER OF WARRANTIES / LIMITATIONS OF LIABILITY 
 8.1 Disclaimer of
Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY OR ITS DIRECTORS, OFFICERS, STOCKHOLDERS, EMPLOYEES, AGENTS OR AFFILIATES MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, ISSUED OR PENDING, NON-INFRINGEMENT OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS
AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY LICENSOR THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE INTELLECTUAL PROPERTY OF ANY THIRD PARTY. 
 8.2 Limitation of Remedies. EXCEPT FOR EITHER PARTY’S OBLIGATIONS UNDER SECTION 9 (INDEMNIFICATION) OR A BREACH OF A PARTY’S OBLIGATIONS
UNDER SECTION 6 (CONFIDENTIAL INFORMATION) IN NO EVENT SHALL EITHER PARTY OR ITS DIRECTORS, OFFICERS, STOCKHOLDERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO
PROPERTY OR LOST PROFITS, REGARDLESS OF WHETHER SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 
 8.3 Limitation of Liability. EXCEPT FOR EITHER PARTY’S OBLIGATIONS UNDER SECTION 9 (INDEMNIFICATION) OR A BREACH OF A PARTY’S OBLIGATIONS UNDER SECTION 6 (CONFIDENTIAL INFORMATION), THE MAXIMUM TOTAL
LIABILITY OF ONE PARTY TO THE OTHER FOR ANY AND ALL CLAIMS RELATING TO OR ARISING UNDER THIS AGREEMENT WILL BE LIMITED TO THE TOTAL AMOUNTS PAID UNDER THIS AGREEMENT. 
 EACH PARTY ACKNOWLEDGES THAT THE OTHER PARTY RELIED UPON THE INCLUSION OF THE LIMITATIONS OF REMEDIES AND LIABILITY SET FORTH IN THIS SECTION 8 IN CONSIDERATION OF ENTERING INTO THIS AGREEMENT. 
  

	***	Confidential treatment requested 

 7 

 9 – INDEMNIFICATION 
 9.1 By Licensee. Licensee shall at all times during the term of this Agreement and thereafter indemnify defend and hold Licensor and its directors, officers, stockholders, employees, agents and affiliates
(collectively, “Licensor Indemnitees”) harmless against any and all liabilities, losses, fines, penalties, damages, expenses of any kind whatsoever, including legal expenses and reasonable attorneys’ fees (collectively,
“Losses”) that arise out of any claim, action, demand, suit, or proceeding brought against a Licensor Indemnitee by any third party after the Effective Date, to the extent attributable to or resulting from Licensee’s
production, manufacture, testing, marketing, sale, distribution, use, consumption, advertisement or promotion of Licensee’s products or services (including, without limitation, any products that contain, incorporate or are based on Peptides).
Licensee’s indemnification obligations under this Section 9.1 shall not apply to any Losses to the extent that they are directly attributable to the grossly negligent activities or intentional misconduct of any of the Licensor Indemnitees.

 9.2 By Licensor. Licensor shall at all times during the term of this Agreement and thereafter indemnify defend and hold Licensee
and its directors, officers, stockholders, employees, agents and affiliates (collectively, “Licensee Indemnitees”) harmless against any and all Losses that arise out of any claim, action, suit, or proceeding brought against a
Licensee Indemnitee by any third party after the Effective Date, to the extent attributable to or resulting from personal injury or death caused by a Peptide considered in isolation (and not attributable to or resulting from the combination of any
Peptide(s) with any other substance or material or any act or omission of Licensee or a Sublicensee). Licensor’s indemnification obligations under this Section 9.2 shall not apply to any Losses to the extent that they are directly
attributable to the grossly negligent activities or intentional misconduct of any of the Licensee Indemnitees. 
 9.3 Certain Procedures
Regarding Indemnification. All claims for indemnification under this Agreement shall be made as follows: 
 (a) In the event a third-party claim, action,
suit, or proceeding is made against a party entitled to indemnification under this Section 9 (the “Indemnitee”) for which the Indemnitee would be entitled to indemnification hereunder (a “Claim”), the
Indemnitee shall notify the Indemnitor of such Claim, specifying the nature and the amount of the Claim (the “Claim Notice”). The Claim Notice must be delivered promptly after the Indemnitee becomes aware of the Claim, provided that
the failure of the Indemnitee to comply with such requirement shall not relieve the party required to indemnify a person under Section 9 (the “Indemnitor”) of its obligations hereunder unless the Indemnitor is materially
prejudiced in the defense of the Claim due to such failure on the part of the Indemnitee. The Indemnitor shall have the right to undertake and control the defense of any Claim at its expense through counsel of its own choosing (subject to the
Indemnitee’s consent to such counsel, which consent may not be unreasonably withheld or delayed). If the Indemnitor undertakes the defense of a Claim: (i) the Indemnitor shall not permit to exist any lien, encumbrance or other adverse
charge upon any asset of the Indemnitee; (ii) the Indemnitor may not settle such action without first obtaining the written consent of the Indemnitee, which consent will not be unreasonably withheld or delayed, except for settlements solely
covering monetary matters for which the Indemnitor acknowledges responsibility for payment; and (iii) the Indemnitor shall permit the Indemnitee (at the Indemnitee’s sole cost and expense) to participate in such settlement or defense
through counsel chosen by the Indemnitee. 
  

	***	Confidential treatment requested 

 8 

 (b) The Indemnitee agrees to preserve and provide access to all evidence in its possession or control that may be useful
in defending against a Claim and to provide reasonable cooperation in the defense thereof or in the prosecution of any action against a third party in connection therewith at the Indemnitor’s expense. The Indemnitor’s defense of any Claim
or demand shall not constitute an admission or concession of liability therefor or otherwise operate in derogation of any rights the Indemnitor may have against the Indemnitee or any third party. So long as the Indemnitor is reasonably contesting
any such Claim in good faith, the Indemnitee shall not pay or settle any such Claim. 
 (c) If the Indemnitor elects not to undertake the defense of the
Claim, the Indemnitee shall have the right to assume the defense of the Claim through counsel of its own choosing and contest, settle or compromise the Claim in the exercise of its exclusive discretion at the expense of the Indemnitor. All
reasonable expenses incurred by the Indemnitee pursuant to this Section 9.3(c) shall be reimbursed by the Indemnitor within twenty (20) days of receipt of competent written evidence of such expenses. 
 10 – INSURANCE 
 10.1 General
Liability. During the term of this Agreement, each Party shall maintain commercial general liability insurance in amounts not less than *** dollars ($***) per occurrence and *** dollars ($***) annual aggregate from an underwriter who has an A.M.
Best rating of A-VII or better, and naming the other Party as an additional insured. Such commercial general liability insurance shall include but not be limited to contractual and product liability coverage for each Party’s indemnification
obligations under Section 9 of this Agreement. The general liability insurance shall include worldwide coverage, including defense of claims and incidents outside of the United States and its territories. The liability policies required under
this Section 10 shall be written as primary and non-contributing to not in excess of any coverage the other Party may choose to maintain. The minimum amounts of insurance coverage required under this Section 10 shall not be construed to
create a limit of each Party’s liability with respect to its indemnification obligations under Section 9 of this Agreement. 
 10.2
Notification. Each Party shall provide the other Party with written evidence of such insurance at any time during the term of this Agreement promptly upon the request of the other Party. Each Party shall provide the other Party with written
notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. If a Party does not obtain replacement insurance providing comparable coverage prior to the expiration of such fifteen (15) day
period, the other Party shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 
 10.3 Term of Insurance. Each Party shall maintain such commercial general liability insurance beyond the expiration or termination of this
Agreement during the period that any products containing, incorporating or based on any Peptide are commercially marketed, distributed or sold by Licensee or any Sublicensee. 
  

	***	Confidential treatment requested 

 9 

 11 – EXPORT CONTROLS 
 Licensee shall comply with and shall, at Seller’s request, demonstrate such compliance with, the U.S. Foreign Corrupt Practices Act and all applicable export laws, restrictions, and regulations of any U.S. or
foreign agency or authority, and shall obtain, and bear all expenses relating to, any necessary licenses and/or exemptions with respect to the export from the U.S. by Licensee or its agents of any Peptide (or any product or material containing,
incorporating or based on any Peptide) or any technology or information it obtains or learns pursuant to this Agreement (or any direct product thereof). 
 12 – MARKS 
 12.1 Non-Use of Marks. Licensee shall not use the names, logos, trademarks or
service marks of Licensor nor any adaptation thereof in any advertising, promotional or sales literature without Licensor’s prior written consent, except that Licensee may state that it is licensed by Licensor hereunder and may identify the
inventors of Licensor’s patents and/or patent applications. 
 13 – TERMINATION 
 13.1 Term. The term of the Agreement shall begin on the Effective Date and shall continue until December 31, 2009, unless terminated at an
earlier date pursuant to the terms and conditions set forth below in this Section 13. This Agreement shall automatically renew for successive one (1) year terms provided the Minimum Royalty Payment requirements set forth in Exhibit
C are achieved in the prior year and unless either Party provides written notice to the other Party at least sixty (60) days prior to the end of the applicable term. 
 13.2 Termination for Breach. Upon any material breach of any provision of this Agreement by a Party (the “Breaching Party”), the
other Party (the “Non-Breaching Party”) shall have a right to give written notice thereof (“Notice of Default”) to the Breaching Party. If the Breaching Party does not cure such material breach within thirty
(30) days after the date of the Notice of Default, the Non-Breaching Party shall have the right to terminate this Agreement by a second written notice (“Notice of Termination”) to the Breaching Party. If the Non-Breaching Party
sends a Notice of Termination to the Breaching Party, this Agreement will automatically terminate on the date of such Notice of Termination. Termination of the Agreement by Licensor under this Section 13.2 shall not relieve Licensee of its
obligation to pay any Royalties or other fees owing at the time of termination, if any, and shall not impair any accrued right of Licensor hereunder. 
 13.3 Termination for Bankruptcy. To the extent permitted by applicable law, each Party shall have the right to immediately terminate this Agreement by giving written notice to the other Party, in the event the
other Party: (i) provides notice of its intent to file (or does actually file without providing said notice) a petition in bankruptcy; (ii) attempts to make an assignment hereof for the benefit of creditors or otherwise;
(iii) discontinues or dissolves its business; or (iv) if a receiver is appointed for it. 
  

	***	Confidential treatment requested 

 10 

 13.4 Effect of Termination. Upon termination or expiration of this Agreement for any reason:
(i) the rights granted to Licensee hereunder shall immediately terminate; and (ii) nothing herein shall be construed to release any party from any obligation that matured prior to the effective date of such termination. 
 13.5 Survival. Sections 2.3, 3, 4.2, 4.5, 6, 8, 9, 15 and 17 of this Agreement shall survive the termination or expiration of this Agreement.

 14 – NOTICES AND OTHER COMMUNICATIONS 
 Any notice or other communication pursuant to this Agreement shall be sufficiently made or given if sent to such Party by certified first class mail, return receipt requested, postage prepaid, by reputable overnight
courier, or by facsimile (with confirmation emission) addressed to it at its address below or as it shall designate by written notice given to the other Party: 
 In the case of Licensor: 
 Helix BioMedix, Inc. 
 22118 20th Avenue SE 
 Suite 204 

Bothell, WA 98021 
 Fax:
(425) 806-2999 
 Attn: President 
 In the case of Licensee: 
 Grant Industries 
 103 Main Avenue 
 Elmwood Park, NJ 07407 
 Fax: (201) 791-0038 
 Attn: President

 All notices sent by first class mail shall be deemed to have been given four (4) business days after deposit, all notices sent by
overnight courier or facsimile shall be deemed to have been given one (1) business day after deposit or transmission, as applicable. 
  

	***	Confidential treatment requested 

 11 

 15 – DISPUTE RESOLUTION 
 Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by arbitration conducted in New York, New
York and administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. Notwithstanding the
foregoing, either Party may, without waiving any remedy under this Agreement, seek from any court having jurisdiction thereof any interim or provisional relief that is necessary to protect the rights or property of that Party from immediate and
irreparable injury, loss, or damage. 
 16 – PRESS RELEASES 
 Neither Party shall issue any press release or other similar public communication relating to this Agreement unless approved in advance and in writing by
the other Party, which approval shall not be unreasonably withheld or delayed, except for those communications required by Applicable Law. 
 17 – MISCELLANEOUS PROVISIONS 
 18.1 Force Majeure. Neither Party shall be held liable or responsible to the other
Party or be deemed to have defaulted under or breached this Agreement for failure to delay in fulfilling or performing any term of this Agreement when such failure of delay is caused by or results from events beyond the reasonable control of the
non-performing Party, including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of terrorism, acts of war (whether war be declared or not), insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances,
acts of God or acts, omissions or delays in acting by any governmental authority. The non-performing Party shall notify the other Party of such force majeure within ten (10) days after such occurrence by giving written notice to the other Party
stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary. 
 18.2 Assignment. Without the prior written consent of the other Party, neither Party shall sell, transfer, assign, delegate, pledge or otherwise
dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that Licensor may assign or transfer this Agreement or any of its rights or obligations
hereunder without the consent of the Licensee to any third party with which it may merge or consolidate, or to which it may transfer all or substantially all of its assets. Any purported assignment or transfer in violation of this Section 18.2
shall be void ab initio and of no force or effect. 
 18.3 Severability. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable,
(b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not
be affected by the illegal, invalid or unenforceable provisions or by its severance herefrom, and (d) in lieu of such 

  

	***	Confidential treatment requested 

 12 

 
illegal, invalid or unenforceable provision there shall be added automatically as a part of this Agreement a legal, valid and enforceable provisions as
similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties herein. To the fullest extent permitted by applicable law, each Party hereby waives any provision of law that would
render any provision prohibited or unenforceable in any respect. 
 18.4 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without giving effect to the conflicts of law provisions thereof. 
 18.5
Entire Agreement. This Agreement sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understating, promises and representations, whether
written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. No amendment, modification, release or discharge
shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 
 18.6 No
Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit hereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the
Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure
by said other Party whether of a similar nature or otherwise. 
 18.7 Attorneys Fees; Equitable Remedies. If either Party brings an
action to enforce any rights arising out of or relating to this Agreement, the prevailing Party in such action shall be entitled to recover from the losing Party its reasonable fees, costs and expenses in connection with such action, including
reasonable attorneys’ fees. The Parties acknowledge and agree that any breach of this Agreement will cause irreparable harm to the non-breaching party, which shall entitle the non-breaching Party to injunctive relief in addition to all other
available legal remedies. 
 18.8 No Benefit to Third Parties. The representations, warranties, covenants and agreement set forth in
this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other parties. 
 18.9 Further Assurances. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do
and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out
more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 
 18.10 Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable 

  

	***	Confidential treatment requested 

 13 

 
to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and
in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used here mean including, without limiting the generality of any
description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. 
 [Signature page follows] 
  

	***	Confidential treatment requested 

 14 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the date set forth above. 
  

									
	HELIX BIOMEDIX, INC.	 		 	GRANT INDUSTRIES
	(“Licensor”)	 		 	(“Licensee”)
					
	By:	 	/s/ R. Stephen Beatty	 		 	By:	 	/s/ David Granatell
	Name:	 	R. Stephen Beatty	 		 	Name:	 	David Granatell
	Title:	 	President & CEO	 		 	Title:	 	Executive Director

 [SIGNATURE PAGE TO FIRST AMENDED AND RESTATED LICENSE AGREEMENT] 

 EXHIBIT A 
 PATENTS, PEPTIDES, AND MINIMUM RECOMMENDED CONCENTRATIONS 
 Patents: 
 *** 
 Peptides: 
  

					
	 Name
	 	 P-No.
	 	 Primary Sequence

			
	 *** (“Peptide A”)
	 	 ***
	 	 ***

			
	 *** (“Peptide B”)
	 	 ***
	 	 ***

			
	 *** (“Peptide C”)
	 	 ***
	 	 ***

 Minimum Recommended Concentrations (for final, marketable formulations after dilution of Premix):

  

	***	

	Maximum	percentage of Peptide in Premix product: ***%. 

  

	***	Confidential treatment requested 

 EXHIBIT B 
 TERRITORY 
 United States 
 Canada 
 Germany 
 France

 United Kingdom 
 Italy 
 Ireland 
 Spain 
 Benelux 
 Switzerland 
 Poland

 China 
 Hong Kong 
 Taiwan 
 South Korea 
 Japan 
 Malyasia 
 Thailand 
 Vietnam 
 Philippines

 Singapore 
  

	***	Confidential treatment requested 

 EXHIBIT C 
 ROYALTY RATES AND MINIMUMS 
 Royalties 

Licensee shall pay to Licensor Royalties in the amount of *** percent (***%) of all Net Revenue, in accordance with the terms set forth in the Agreement. 

Minimum Royalty Payments: 
 Licensor shall have the right to
terminate this Agreement and/or remove a Peptide from Exhibit A (at Licensor’s option) if Licensee fails to make the following minimum royalty payments for the applicable calendar year during the term of this Agreement (provided that the
minimum amounts for 2006 and 2007 shall include payments made or accrued under the Prior Agreement): 
             *** 
 Should Licensor exercise its right to terminate this Agreement
or remove a Peptide from Exhibit A due to Licensee’s failure to meet minimum royalty payments, Licensee may, during the one-year period following notice from Licensor to Licensee of such termination or removal, continue to sell Premix
(or Premix containing such removed Peptide, as the case may be) solely to Sublicensees existing as of the date of such notice, subject to the other terms of this Agreement. 
  

	***	Confidential treatment requested 

 EXHIBIT D 
 ROYALTY REPORT 
 Monthly Sales Report – Grant Industries 
 For the month 
 of: 

															
	 Date
	  	 Customer
Name
	  	 Peptide
Description
	  	 Peptide Conc
in Premix
	  	 Premix
Amount (kg)
	  	Net
Revenue	  	Royalty
Rate (***%)
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  			  	 	—  
		  		  		  		  		  	 	 	  	 	 
	 Total
	  		  		  		  		  	$	—  	  	$	—  
		  		  		  		  		  	 	 	  	 	 

  

	***	Confidential treatment requestedLicense Agreement

 Exhibit 10.27 
 LICENSE AGREEMENT 
 This License Agreement (the
“Agreement”) is entered into as of August 16, 2007 (the “Effective Date”) between Goldschmidt GmbH, a German company with its principle place of business at Goldschmidtstrasse 100, 45127 Essen, Germany (“Licensee”)
and Helix BioMedix, Inc., a Delaware, United States corporation with its principle place of business at 22118 20th Avenue SE, Suite 204, Bothell, WA 98021,
U.S.A. (“Licensor”). 
 1. Certain Definitions. 
 1.1 “Affiliate” of a party means an entity directly or indirectly controlling, controlled by or under common control with that party, where control means the ownership or control, directly or
indirectly, of more than 50% of all of the voting power of the shares (or other securities or rights) entitled to vote for the election of directors or other governing authority, as of the Effective Date of this Agreement or hereafter during the
term of this Agreement; provided that such entity shall be considered an Affiliate only for the time during which such control exists. 
 1.2
“Combination(s)” means any product combination made by incorporation of one or more other active ingredient(s) with a Product. 
 1.3 “Disclosing Party” means a party hereto that discloses its Proprietary Information to the other party. 
 1.4
“Final Formulations” means any final personal care formulation made by customers of Licensee that incorporates one or more Peptides (themselves incorporated in Product(s) or Combination(s)) and that is marketable to end customers as
a cosmetic or, as the case may be in certain jurisdictions, as a non-prescription drug if qualified as such under the relevant national regulatory system. 
 1.5 “Improvements” means any and all new experiences, findings, improvements, modifications, developments and/or inventions, whether patentable or not, pertaining to Peptides. Notwithstanding the
foregoing: (i) Improvements shall not include specific formulations, including but not limited to Products, Combinations and Final Formulations, developed by either party or its customers respectively, containing any Peptide; and
(ii) Improvements shall include peptides and other molecules other than the Peptides (as defined herein) only if such an additional peptide or other molecule is derived from a Peptide claimed in the First Application. 
 1.6 “Licensed Area” means the use of any Peptide, Product or any Combination in a Final Formulation that is marketable to end customers
as a cosmetic or, as the case may be in certain jurisdictions, as a non-prescription drug if qualified as such under the relevant national regulatory system. 
  

  

 Confidential treatment has been requested for portions of this exhibit. This exhibit omits the information subject to the confidential treatment request. Omissions are designated as ***. A complete version of this
exhibit has been filed separately with the Securities and Exchange Commission. 

 1.7 “Net Sales Value” means: *** 
 1.8 “Peptide(s)” means any of Licensor’s proprietary bioactive peptides claimed in the Subject IP. 
 1.9 “Product(s)” means any formulation, such as but not limited to any dispersion, solution or gel, incorporating one or more Peptides
as active ingredients, that is made by or for Licensee and marketed by Licensee to third parties solely for use in Final Formulations. 
 1.10 “Proprietary Information” of a Disclosing Party means the following, to the extent previously, currently or subsequently disclosed to the other party hereunder or otherwise: information relating to (i) Products,
ingredients, items, substances and Combinations thereof developed, produced and/or sold by the Disclosing Party, in particular their properties, composition, or structure of technology or the manufacture or processing thereof or machines therefor or
(ii) to the Disclosing Party’s business (including, without limitation, names and expertise of employees and consultants, know-how, formulas, processes, ideas, inventions (whether patentable or not), schematics, and other technical,
business, financial, customer and product development plans, forecasts, strategies and information). In particular, but without limitation, the Peptides and their properties, composition, or structure, and the Technology, are Proprietary Information
of Licensor. 
 1.11 “Receiving Party” means a party hereto that receives Proprietary Information of the other party.

 1.12 “Royalty Period” shall mean, throughout the term of this Agreement, semi-annual periods starting from January 1
until June 30 and July 1 until December 31. If this Agreement ends in between such periods the last Royalty Period shall end at the same time as this Agreement. 
 1.13 “Subject IP” means the US patent applications No. *** (“First Application”) and No. *** (“Second
Application”) and any continuations, divisionals, reissues, registrations, confirmations, term extensions or reexaminations thereof, any subsequent filings in any country claiming priority therefrom, and any and all discoveries or
inventions embodied within the foregoing that are owned by Licensor as of the Effective Date; provided that Subject IP excludes continuations-in-part. Notwithstanding the foregoing, with respect to the Second Application, Subject IP includes only
the peptides *** and the associated rights covered by the Second Application. 
 1.14 “Technology” means inventions (whether
or not patentable), ideas, processes, formulas and know-how owned by Licensor as of the date of this Agreement and relating to the Peptides. 
 1.15 “Territory” means ***. 
  

	***	Confidential treatment requested 

 2 

 2. License Grant. Subject to all the terms and limitations of this Agreement, Licensor hereby grants Licensee a
license under the Subject IP and the Technology within the scope described in this Section 2 and Section 3. This license is limited to and may be exercised solely for the purposes of: (i) performing evaluation and testing of the
Peptides to determine their suitability as ingredients in Products, Combinations and Final Formulations, including without limitation toxicity and effectiveness tests and trials; (ii) making Peptides or having made Peptides by a
toll-manufacturer and/or sourcing Peptides from third parties (in each case at Licensee’s expense); provided that any toll-manufacture by or sourcing of Peptides from a company that is not located in *** shall require the prior approval of
Licensor; (iii) making, or having made by a toll-manufacturer, Products and/or Combinations; and (iv) marketing (including selling and offering to sell) Products and Combinations solely in the Licensed Area and solely in (including
importing and exporting them within) the Territory. Licensee will not make or market Final Formulations. Licensee will notify Licensor promptly after the engagement of any toll-manufacturer or other third party as provided in subsections
(ii) and (iii) above, such notice to include the identity of such third party and the manufacturing tasks for which the third party is engaged. 
 3. License Scope. Licensee’s license is exclusive (including as against Licensor) for the purposes stated in Section 2(iii) and (iv) and includes the right to grant sublicenses to Licensee’s worldwide customers
solely to permit those customers to use the Products and Combinations and to make or have made and to market or have marketed Final Formulations (but not to market or otherwise distribute the Products or Combinations other than as incorporated into
Final Formulations). 
 4. Right of First Offer. Licensor will promptly notify Licensee of any additional peptide or other molecule that is derived
from a peptide or peptides claimed in the Second Application, that has ***, and that is developed by or for Licensor within a period of 5 (five) years from the Effective Date (a “Subject Peptide”). Licensee may, within 60 (sixty)
days of such notice from Licensor, notify Licensor that Licensee wishes to negotiate for an exclusive license to the Subject Peptide(s) (the “Licensee ROFO Notice”). The parties agree to negotiate in good faith for the exclusive
license to Licensee of the Subject Peptide(s) during the 60 (sixty) day period following the effectiveness of the Licensee ROFO Notice. If (i) the Licensee ROFO Notice is not timely given by Licensee or (ii) the parties do not enter into a
written agreement for such license during such 60-day period, the right of first offer described in this section shall terminate with respect to the Subject Peptide(s) that is/are the subject of Licensor’s particular offer and such Subject
Peptide(s) shall, as between the parties, be and remain the sole property of Licensor without restriction. 
 5. Improvements. Any Improvements
(whether or not patentable or copyrightable) that either party develops shall be owned solely by such party. Such party shall have the right, at its own expense and solely in its own name, to apply for, prosecute and defend its proprietary rights
with respect thereto. Each party will promptly disclose to the other party any Improvements made by or for it within a period of 5 (five) years from the Effective Date. Each party hereby licenses to the other party any Improvements made 

  

	***	Confidential treatment requested 

 3 

 
by or for it during such 5-year period as follows: (i) Licensor hereby grants to Licensee a worldwide, royalty-free, non-exclusive, perpetual license to
fully exploit any such Improvements that are within the Licensed Area; and (ii) Licensee hereby grants back to Licensor a worldwide, royalty-free, non-exclusive, perpetual license to fully exploit any such Improvements that are outside the
Licensed Area (provided that this provision will not be deemed to grant to either party any right or license not expressly granted herein, including, without limitation, any right to disclose Proprietary Information of the respective other party).

 6. Marketing Efforts. Licensee will use reasonable commercial efforts to successfully market Products and/or Combinations on a continuous basis for
incorporation into Final Formulations by its customers under its license. As part of such efforts, but without limitation, Licensee will feature the Products and/or Combinations in a prominent location in its relevant catalogs, actively seek
customers for Products and/or Combinations, and provide formulary and sales support to its customers at levels meeting or exceeding industry standards. 
 7.
Marks; Marking. 
 7.1 Except as expressly provided herein or subsequently authorized by Licensor in writing, (i) Licensee will
not use or register any mark, name, or designation of Licensor anywhere in the world and (ii) Licensee has no right or license with respect to any mark, name, or designation of or used by Licensor. Use of any Licensor mark and any related
goodwill will inure to Licensor’s benefit. 
 7.2 Unless otherwise indicated by Licensor in writing, Licensee will mark all Product and
Combination packaging, in easily readable, non-obscured type, with applicable patent notices (including “pat.” or “patent” and the applicable patent numbers) and notices of patent pending. In addition, Licensee will ask its
customers to mark all packaging of Final Formulations in the same manner as described above. 
 8.***; Royalties; Audit. 
 8.1*** 
 8.2*** 
  

	***	Confidential treatment requested 

 4 

 8.3 Licensee will pay Licensor a running royalty on Net Sales Value from the sale or other disposition of
Products and Combinations at the following rates with respect to the following periods during the term hereof: 
  

			
	 Years (from the Effective Date)
	  	Royalty Rate
	 1 through 5
	  	*** percent
	 6 through 10
	  	*** percent
	 11 through 15
	  	*** percent
	 16 and thereafter
	  	*** percent

 If the grant of a patent covering all or part of the Subject IP in a particular region or country is revoked or
such a patent is abandoned, but a patent application pertaining to Subject IP and covering at least one Peptide, Product or Combination being commercialized by Licensee hereunder is pending in such region or country, the applicable royalty rate as
set forth in this Section 8.3 after the date of revocation or abandonment shall be reduced by *** with respect to such region or country as to any affected Product or Combination, unless and until a patent as to such region or country
pertaining to Subject IP and covering such Peptide Product or Combination is in place and the necessary rights therein are controlled by Licensor or Licensee; provided that such reduction shall not apply to any Product or Combination that contains
any Peptide that is not affected by such revocation or abandonment. If a patent or patents covering the Subject IP in a particular region or country is/are finally revoked or finally abandoned and no patent application or patent covering at least
one Peptide Product or Combination being commercialized by Licensee hereunder is pending in such region or country, *** 
 8.4 Licensee
guarantees that earned running royalties will equal or exceed a minimum amount of US-$*** US dollars) with respect to the period from the Effective Date through the end of 2010 (the “Initial Period”). If earned running royalties
with respect to the Initial Period fall short of the minimum amount specified above, then Licensee shall pay to Licensor, within 30 days after the end of 2010, the difference between such earned running royalties and such minimum amount, it being
understood that total payment required pursuant to this Section 8.4 for the Initial Period will not exceed the minimum amount specified above. 
 The
parties will negotiate in good faith to agree upon minimum royalties with respect to each of calendar years 2011 through 2013 by the end of the Initial Period, and thereafter with respect to each individual calendar year of each three-calendar-year
period remaining during the term hereof (and any shorter period that may remain at the end of the term hereof), such agreement to be reached in each case not later than the end of the last calendar year as to which minimum royalties then apply. The
parties shall enter into such negotiations 4 (four) months before the end of the Initial Period or, with respect to any other period, 4 (four) months before the end of the prior period as to which agreement has been reached. Provided an agreement
has been reached, if as to any calendar year during the term after 2010 earned running royalties fall short of the minimum amount agreed with respect to such calendar year, then Licensee shall pay to Licensor, within 30 days after the end of such
calendar year of shortfall, the difference between such earned running royalties and the minimum amount agreed for such calendar year, it being understood that total payment required pursuant to this Section 8.4 for the calendar year of
shortfall will not exceed the minimum amount agreed upon for such calendar year. 
  

	***	Confidential treatment requested 

 5 

 If such agreement is not reached with respect to 2011 through 2013 by the end of the Initial Period, or with respect to
any other three-year period before the end of the prior period as to which agreement has been reached, then with respect to any such failure to agree the license granted to Licensee hereunder shall become nonexclusive, effective from the beginning
of the first calendar year as to which no such agreement was reached and continuing until the termination or expiration of this Agreement. Further, any and all requirements with respect to minimum royalties and each party’s rights and
obligations relating thereto according to this Section 8.4 or any other section of this Agreement shall terminate automatically at the time the license becomes nonexclusive (except that rights accrued to that time will not be affected).

 No claim for a minimum royalty payment, either in whole nor in part, shall arise according to this Section 8.4, if this Agreement is terminated in
accordance with Section 12.2(ii), 12.3(i) or 12.3(ii). 
 8.5 Running Royalties as set forth in Section 8.3 shall be paid within 30
(thirty) days of the end of a Royalty Period with respect to royalty-bearing sales occurring in that period, and will be accompanied by a statement indicating the associated Net Sales Value and royalties payable (including currency conversions),
itemized by Products and Combinations, and also identifying the Licensee customers or other third parties to which such Net Sales Value is attributable and the amount of such Net Sales Value that is attributable to each such customer or other third
party. Royalties shall be paid by Licensee in U.S. dollars, with currency conversions calculated based upon the applicable closing exchange rates quoted by the Deutsche Bank foreign exchange desk on the last business day of the applicable Royalty
Period. Any amount payable hereunder that is not paid on the date that it becomes due will bear interest, calculated based on the number of days such payment is late and compounded monthly, at a rate of the lesser of (i) 0.5 % per month or
(ii) the maximum rate permitted by applicable law. 
 8.6 The payments to be made by Licensee to Licensor pursuant to this Agreement
shall not be reduced by any taxes, expenses, fees or other withholdings levied upon said payments under the laws of the Federal Republic of Germany, unless all of the following requirements are met: (i) The amount by which the payments are
reduced is a tax imposed on income and is not an excise, franchise, turnover, value added tax or any other type of levy or duty; (ii) the tax is imposed on Licensor under the laws of the Federal Republic of Germany and the Double Taxation
Convention between the Federal Republic of Germany and the U.S.A., and Licensee is required by law to withhold the tax from payments to Licensor and to pay the tax withheld to the relevant tax authorities; and (iii) Licensee furnishes to
Licensor, without undue delay, a tax receipt for the tax withheld. All taxes, licenses, fees or other levies and duties imposed upon or which arise because of payments to Licensor by Licensee under the laws of the Federal Republic of Germany, other
than those which meet the above requirements shall be paid and absorbed by Licensee. All taxes, licenses, fees or other levies or duties imposed upon such payments under the laws of the United States of America 

  

	***	Confidential treatment requested 

 6 

 
shall be borne by Licensor. The parties acknowledge and agree that as of the Effective Date, the applicable Double Taxation Convention withholding rate is
0%, and that as such no withholding by Licensee as described in this section will by made by Licensee absent a change in the Double Taxation Convention, provided the German tax authorities have issued to Licensee an official certificate of exemption
(“Freistellungsbescheinigung”). 
 8.7 Within 20 (twenty) days after the beginning of each calendar quarter, Licensee will
report to Licensor the Net Sales Value generated during the previous calendar quarter, and identifying the associated customers or other third parties to which such Net Sales Value is attributable and the amount of such Net Sales Value that is
attributable to each such customer or other third party. 
 8.8 Licensee shall keep and maintain detailed and accurate books and records with
regard to Net Sales Value, royalties, and the calculation thereof. A reputable independent certified public accounting firm selected by Licensor shall be entitled to review and audit such books and records from time to time during normal business
hours upon reasonable notice to Licensee and at Licensor’s expense for the sole purpose of confirming the accuracy and completeness of all royalty payments; provided that Licensee will bear any such expense if the review or audit shows an
underpayment of more than 5% for any Royalty Period or in the aggregate. 
 9. No Restriction on Competition; Nonsolicitation. Nothing in this
Agreement shall be deemed to prohibit Licensee from developing, making, using, marketing or otherwise distributing or promoting products competitive with Products and/or Combinations or Final Formulations produced hereunder, provided that Licensee
does not breach any provision of this Agreement (including, without limitation, Section 10 (Confidentiality) or disparage the Peptides or any Products and/or Combinations or Final Formulations produced hereunder. However, during the term of
this Agreement and for one year thereafter, neither party, will solicit any employee or consultant of the other to leave the employ of the other; the foregoing does not prohibit mass media “want ads” not specifically directed towards
employees or consultants of a party. 
 10. Confidentiality. Each party recognizes the confidential nature of the other party’s Proprietary
Information, the importance to the business of the other party and that neither party would enter into this Agreement without assurance that such information and the value thereof will be protected as provided in this Section 10 and elsewhere
in this Agreement. 
 Accordingly, each party agrees as follows: 
 10.1 The Receiving Party agrees: (i) to hold the Disclosing Party’s Proprietary Information in confidence and to take reasonable precautions to protect such Proprietary Information (including, without
limitation, all precautions the Receiving Party employs with respect to its confidential materials); (ii) not to divulge (except to Affiliates, customers, and toll-manufacturers of Licensee as far as necessary for Licensee to 

  

	***	Confidential treatment requested 

 7 

 
practice the rights granted under its license hereunder, provided that such Affiliates, customers or toll-manufacturers have first entered into a
confidentiality agreement with Licensee with provisions no less restrictive than those set forth in this Section 10) any such Proprietary Information or any information derived therefrom to any third person except as expressly authorized in
this Agreement; (iii) not to make any use whatsoever at any time of such Proprietary Information except as expressly authorized in this Agreement; and (iv) not to remove or export from the United States or reexport any such Proprietary
Information or any direct product thereof (e.g., Peptides, or Products and/or Combinations or Final Formulations by whomever made) except in compliance with and with all licenses and approvals required under applicable U.S. and foreign export laws
and regulations, including without limitation, those of the U.S. Department of Commerce. Any employee given access to any such Proprietary Information must have a legitimate “need to know” and shall be similarly bound in writing if he/she
is not already bound by confidentiality and restricted-use terms not less severe than those stipulated herein. 
 10.2 Without granting any
right or license, the Disclosing Party agrees that clauses (i), (ii) and (iii) of Section 10.1 shall not apply with respect to information the Receiving Party can document: (i) is in or (through no improper action or inaction by
the Receiving Party or any Affiliate, agent or employee) enters the public domain (and is readily available without substantial effort); or (ii) was rightfully in its possession or known by it prior to receipt from the Disclosing Party; or
(iii) was rightfully disclosed to it by another person without restriction; or (iv) was independently developed by it by persons without access to such information and without use of any Proprietary Information of the Disclosing Party. The
Receiving Party must promptly notify the Disclosing Party of any information it believes comes within any circumstance listed in the immediately preceding sentence and will bear the burden of proving the existence of any such circumstance by clear
and convincing evidence. In addition, the Receiving Party may make disclosures required by law, provided that the Receiving Party gives the Disclosing Party prompt written notice of such requirement prior to such disclosure, uses reasonable efforts
to limit disclosure and to obtain confidential treatment or a protective order, and has allowed the Disclosing Party to participate in the proceeding. Each party’s obligations under Section 10.1 will apply only to disclosures made during
the term of this Agreement; however, such obligations will continue for a period of 10 (ten) years from the date of first disclosure with respect to disclosures made during that period. 
 10.3 Immediately upon termination of this Agreement, the Receiving Party will turn over to the Disclosing Party all Proprietary Information of the
Disclosing Party and all documents or media containing any such Proprietary Information and any and all copies or extracts thereof. 
 10.4
The Receiving Party acknowledges and agrees that due to the unique nature of the Disclosing Party’s Proprietary Information, there can be no adequate remedy at law for any breach of its obligations hereunder, that any such breach may allow the
Receiving Party or third parties to unfairly compete with the Disclosing Party 

  

	***	Confidential treatment requested 

 8 

 
resulting in irreparable harm to the Disclosing Party, and therefore, that upon any such breach or any threat thereof, the Disclosing Party shall be entitled
to appropriate equitable relief (without the posting of any bond) in addition to whatever remedies it might have at law and to be indemnified by the Receiving Party from any loss or harm, including, without limitation, lost profits and reasonable
attorney’s fees, in connection with any breach or enforcement of the Receiving Party’s obligations hereunder or the unauthorized use or release of any such Proprietary Information. The Receiving Party will notify the Disclosing Party in
writing immediately upon the occurrence of any such unauthorized release or other breach. Any breach of this Section 10 will constitute a material breach of this Agreement. 
 11. Patent Matters; Third Party Rights. 
 11.1 Licensor retains the sole right and discretion to file
and prosecute patent applications and maintain patents in the Territory relating to the Peptides, Subject IP and Technology and any Improvements or other developments or inventions made by or for Licensor, except as otherwise set forth in the
following sentence. Licensee will not attempt to file or prosecute any such patent applications or maintain any such patent (i) except as Licensor may, at its sole discretion, approve in writing and (ii) except that Licensee may continue
maintenance of patents issued in the Territory and licensed hereunder and may file and prosecute patent applications covering Peptides, in each case if Licensor elects not to do so, and at Licensee’s expense. Licensor shall notify Licensee, in
due time before the expiry of the international phase of the PCT procedure, as to which PCT countries Licensor will seek patents in the national phase of the PCT procedure so that Licensee may seek patent protection in the countries as to which
Licensor does not elect to seek such protection. Licensee shall pay for Net Sales Value of Products and Combinations with respect to sales or other dispositions into countries where it maintains such patents or files and prosecutes such applications
a royalty at ***% of the otherwise applicable royalty rate. 
 11.2 Licensor agrees to file, and make reasonable commercial efforts to
prosecute national patent applications and maintain any patents granted upon such applications, at least for the countries listed in Exhibit A. 
 11.3 If Licensee becomes aware of any product or activity of any third party that may involve infringement or violation of any Subject IP in the Territory, then Licensee shall promptly notify Licensor in writing of
such actual or potential infringement or violation. Licensor may in its discretion take or not take whatever action it believes is appropriate in response to any actual or potential infringement or violation of Subject IP; if Licensor elects to take
action, Licensee will fully cooperate therewith at Licensor’s expense, including joining as a party if necessary. 
 11.4 If Licensor
does not, within 90 days after receipt of a notice from Licensee in accordance with Section 11.3 of a patent infringement within the scope of the then-remaining exclusivity of Licensee’s license hereunder, commence action directed toward
restraining or enjoining such infringement of Subject IP, Licensee, so long as 

  

	***	Confidential treatment requested 

 9 

 
such exclusivity remains in effect, may take such legally permissible action as it deems necessary or appropriate to enforce the Subject IP and restrain such
infringement. Licensor agrees to cooperate reasonably, at Licensee’s expense, in any such action Licensee initiates or wishes to initiate, including supplying essential documentary evidence and making essential witnesses then in Licensor’s
employment available. As part of such cooperation, Licensee may join or include Licensor as a party if necessary, although such joinder or inclusion shall be entirely at Licensee’s expense. Nothing in this Section 11.4 allows Licensee or
requires Licensor to disclose Proprietary Information of Licensor. 
 11.5 If Licensor initiates and prosecutes any action under
Section 11.3, all legal expense (including court costs and attorneys’ fees) shall be borne by Licensor and Licensor shall be entitled to all amounts awarded by way of judgment, settlement or compromise. Similarly, if Licensee initiates and
prosecutes an action under Section 11.4, all legal expenses (including court costs and attorneys’ fees) shall be borne by Licensee and Licensee shall be entitled to all amounts awarded by way of judgment, settlement, or compromise.

 11.6 Licensor and Licensee agree to work cooperatively regarding issues concerning Subject IP and similar matters and to exercise
reasonable business judgment in carrying out the objectives of this Agreement to avoid exposing either party to liability under patent or similar laws in any of the countries in the Territory. 
 11.7 Licensor shall be responsible for a freedom to operate study concerning all Peptides that have passed the Toxicity Tests (as defined in
Section 12.3(i)), with a scope to include ***. Licensor will make reasonable commercial efforts to determine the initial results of such study within 60 days after the Toxicity Tests have been completed and notice of the results of the Toxicity
Tests has been given by Licensee to Licensor, and to finalize such study within 60 days after such initial results are due hereunder. Licensor shall disclose to Licensee promptly after determination of initial results and after completion of the
entire study the results of such freedom to operate study to the extent that Licensor determines such disclosure may be made without waiving any legal privilege (and any such information disclosed shall in any event be Proprietary Information of
Licensor). The costs of such freedom to operate study conducted by Licensor shall be borne by Licensor. 
 Licensee shall be responsible for a freedom to
operate study concerning all Peptides that have passed the Toxicity Tests, with a scope to include ***. Licensee will make reasonable commercial efforts to determine the initial results of such study within 60 days after completion of the Toxicity
Tests, and to finalize such study within 60 days after such initial results are due hereunder. Licensee shall disclose to Licensor promptly after its completion the results of such freedom to operate study to the extent that Licensee determines such
disclosure may be made without waiving any legal privilege (and any such information disclosed shall in any event be Proprietary Information of Licensee). Licensee shall be responsible for any freedom to operate study concerning the Peptides that
have passed the Toxicity Tests outside the territories of ***, and 

  

	***	Confidential treatment requested 

 10 

 
further for any freedom to operate study concerning Peptides Licensee elects to commercialize other than those that pass the Toxicity Tests, with respect to
any country in the Territory. Licensee shall furthermore be responsible for any freedom to operate study concerning any Products and Combinations in the Territory. Licensee may decide at its own discretion for which countries of the Territory it
shall carry out such studies depending on the results of its worldwide patent searches. The costs of all such freedom to operate studies conducted by Licensee shall be borne by Licensee. 
 12. Term and Termination. 
 12.1 This Agreement will remain in effect from the Effective Date until
the expiration of the last-to-expire patent included in the Subject IP licensed hereunder, unless terminated pursuant to this Section 12. 
 12.2 Either party may terminate this Agreement: 
 (i) upon 30 days’ notice if for any period of three
consecutive years after 2010 during the term of this Agreement earned running royalties fall short of the minimum amounts agreed to pursuant to Section 8.4 with respect to each of such three years (regardless of whether such shortfall has been
paid by Licensee as required by Section 8.4), provided Licensee still holds an exclusive license at that time. Notice of termination under this Section 12.2(i) must be given within 60 days after the end of any such consecutive three-year
period of shortfall. No claim for a minimum royalty payment, either in whole nor in part, shall arise for the calendar year in which such termination becomes effective. 
 (ii) upon notice to the other party if such party concludes, in its reasonable discretion, that the freedom to operate studies for *** to
be performed pursuant to Section 11.7 reveal a serious risk of future patent infringement from the commercialization of the Peptides that have passed the Toxicity Tests and, in consequence thereof, a Peptide portfolio consisting of a minimum of
one Peptide from the First Application (*** to be considered as “one” Peptide) and one Peptide from the Second Application (a “Minimum Peptide Portfolio”) (a) can be reasonably marketed neither in ***; or (b) can
only be reasonably marketed in ***, but not in ***; or (c) can only be reasonably marketed in *** but not in ***, due to such infringement risk. Notice of termination under this Section 12.2(ii) must be given within 60 (sixty) days after
each party’s disclosure of the final results of the freedom to operate study to be performed by such party in accordance with Section 11.7. In case none of the Peptides that pass the Toxicity Tests can be reasonably marketed due to a risk
of future patent infringement, Licensee may request from Licensor a refund of *** payments already made by Licensee to Licensor according to Section 8.1 upon termination. 
 (iii) upon 30 days’ notice, if a party materially breaches a material provision of this Agreement (including without limitation any
breach of Licensee’s obligation to pay running royalties in accordance with Section 8) unless the breach is cured within the notice period. 
  

	***	Confidential treatment requested 

 11 

 12.3 In addition to the termination rights stipulated in Section 12.2, Licensee may immediately
terminate this Agreement: 
 (i) upon notice to Licensor given within 30 days after completion of the Toxicity Tests, but no later than
October 31, 2007, if the results of toxicity testing (AMES tests) on following Peptides claimed in the First Application, namely ***, together with the results of the toxicity testing (AMES tests) already performed with respect to ***
(together, the “Toxicity Tests”), are such that a Peptide portfolio consisting of at least two Peptides (*** to be considered as “one” Peptide) from the First Application and at least one Peptide from the Second
Application (a “Larger Peptide Portfolio”) ultimately has not passed the Toxicity Tests. Licensee shall be entitled to terminate the Agreement according to this Section 12.3(i), even if the Minimum Peptide Portfolio as defined
12.2(ii) has passed the Toxicity Tests. Furthermore, if a Larger Peptide Portfolio has not passed the Toxicity Tests, Licensee’s obligation to make *** payments according to Section 8.1 shall be reduced to ***% (*** percent) of the amounts
specified in Section 8.1. If Licensee has already submitted such *** payments to Licensor by the time of giving notice, Licensee may request a refund of ***% (*** percent) of the *** payments already made. 
 (ii) upon notice to Licensor given within 60 (sixty) days after each party’s disclosure of the final results of the freedom to operate study to be
performed by such party in accordance with Section 11.7, if Licensee, in its reasonable discretion, concludes, based on the results of the freedom to operate studies that the Larger Peptide Portfolio (as defined in 12.3 (i)), having passed the
Toxicity Tests, (a) can reasonably be marketed neither in ***; or (b) can only be reasonably marketed in ***, but not in ***; or (c) can only be reasonably marketed in ***, but not in ***, due to an infringement risk. Licensee shall
be entitled to terminate the Agreement according to this Section 12.3 (ii), even if, as a conclusion from the results of the freedom to operate studies, the Minimum Peptide Portfolio (as defined 12.2 (ii)), having passed the Toxicity Tests,
would be marketable in ***. 
 12.4 In the event of any termination of this Agreement, all the rights and licenses granted Licensee under
this Agreement and Licensee’s obligation under Section 6 shall terminate and Licensor’s obligations to negotiate or provide goods, services, facilities, technology or information shall cease but all other provisions of this Agreement
will continue in accordance with their terms. Notwithstanding the foregoing, upon termination Licensee shall be entitled to finish all Products and Combinations which are already under manufacture at the date of the termination notice, and to
continue the sale of the Products/ Combinations for a period of not more than 9 (nine) months thereafter, unless Licensor has terminated this Agreement according to Section 12.2 (iii). Licensee’s obligations to make royalty payments
pursuant to Section 8 and Licensor’s right to verify the royalty payments as set out in Section 8.8 shall remain unaffected. 
 12.5 Neither party shall incur any liability whatsoever for any damage, loss or expenses of any kind suffered or incurred by the other arising from or incident to any termination of this Agreement (or any part thereof) by such party which
complies with the terms of the Agreement whether or not such party is aware of any such damage, loss or expenses. 
  

	***	Confidential treatment requested 

 12 

 12.6 Termination is not the sole remedy under this Agreement and, whether or not termination is effected,
all other remedies will remain available. 
 13. Warranties and Representations  
 13.1 Licensor warrants and represents that, as of the Effective Date: 
 (i) it owns the entire right, title and interest in each Peptide and the Subject IP hereunder, free and clear of any claim or right of any
third party, including any governmental authority; 
 (ii) it has the sole and exclusive right to enter into and to perform
this Agreement; 
 (iii) it has not entered into any agreement, commitment or understanding that would preclude, frustrate or
impede the ability of the parties to enter into and perform this Agreement; 
 (iv) it has not provided, directly or
indirectly, any Peptides, samples thereof or any Proprietary Information relating to Technology to any third party other than under confidentiality and use restrictions at least as rigorous as those in the Confidentiality Agreement entered into by
the parties on April 12, 2006; 
 (v) it has no knowledge of any infringement by any third party of the Subject IP; and

 (vi) to it’s knowledge, the Peptides themselves (considered in isolation from their use in any Product, Combination,
Final Formulation or otherwise) do not infringe the intellectual property rights of any third party existing as of the Effective Date of this Agreement. 
 13.2 Licensee warrants and represents that, as of the Effective Date: 
 (i) it has the sole
and exclusive right to enter into and to perform this Agreement; and 
 (ii) it has not entered into any agreement, commitment
or understanding that would preclude, frustrate or impede the ability of the parties to enter into and perform this Agreement. 
 13.3 If due
to an actual or potential infringement of a third party intellectual property right by commercialization of a Peptide, Licensee is no longer reasonably able to sell a Product or Combination incorporating such Peptide and Licensor does not 

  

	***	Confidential treatment requested 

 13 

 
provide to Licensee a non-infringing Peptide which is acceptable to Licensee as a suitable alternative to the infringing Peptide, the minimum royalties (to
the extent then agreed upon and in place) applicable pursuant to Section 8.4 to the period during which such sales may thereafter not reasonably be made, shall be reduced according to the portion of total Net Sales Value generated by the
Product or Combination incorporating the infringing Peptide over the most recent calendar year during which such sales were made, applied pro rata. 
 14.
Indemnification. 
 14.1 Licensor shall indemnify, defend and hold Licensee harmless from any claims, demands, lawsuits, charges or
damages (including attorneys’ fees and expenses) (collectively “Costs”) arising out of or relating to infringement by the Peptides per se (considered in isolation from their use in any Product, Combination, Final Formulation or
otherwise), through Licensee’s commercialization of Products or Combinations as permitted hereunder, of the intellectual property rights of any third party; provided that the aggregate liability of Licensor under this Section 14.1 and
Section 14.3 shall not exceed *** 
 14.2 Licensee shall be responsible for compliance with all applicable laws and regulations relating
to the manufacture, labeling, commercialization, transportation, sale and use of Peptides, Products and Combinations by or for Licensee and, as applicable, for obtaining any necessary government permits or licenses for such activities. Licensee
shall indemnify, defend and hold Licensor harmless, from any Costs arising out of or relating to the manufacture, labeling, commercialization, transportation, sale or use of Peptides, Products and Combinations by or for Licensee, including without
limitation product liability and infringement claims of third parties, to the extent that such infringement claims are not based on an infringement of third party rights by a Peptide per se (considered in isolation from its use in any Product,
Combination, Final Formulation or otherwise) incorporated in such Product or Combination. 
 14.3 All claims for indemnification under this
Agreement shall be made as follows: 
 (i) In the event a third-party claim, action, suit, or proceeding is made against a
party entitled to indemnification under this Section 14 (the “Indemnitee”) for which the Indemnitee would be entitled to indemnification hereunder (a “Claim”), the Indemnitee shall notify the Indemnitor of such
Claim, specifying the nature and the amount of the Claim (the “Claim Notice”). The Claim Notice must be delivered promptly after the Indemnitee becomes aware of the Claim, provided that the failure of the Indemnitee to comply with
such requirement shall not relieve the party required to indemnify a person under Section 14 (the “Indemnitor”) of its obligations hereunder unless the Indemnitor is materially prejudiced in the defense of the Claim due to such
failure on the part of the Indemnitee. The Indemnitor shall have the right to undertake and control the defense of any Claim at its expense through counsel of its own choosing 

  

	***	Confidential treatment requested 

 14 

 
(subject to the Indemnitee’s consent to such counsel, which consent may not be unreasonably withheld or delayed). If the Indemnitor undertakes the
defense of a Claim: (i) the Indemnitor shall not permit to exist any lien, encumbrance or other adverse charge upon any asset of the Indemnitee; (ii) the Indemnitor may not settle such action without first obtaining the written consent of
the Indemnitee, which consent will not be unreasonably withheld or delayed, except for settlements solely covering monetary matters for which the Indemnitor acknowledges responsibility for payment; and (iii) the Indemnitor shall permit the
Indemnitee (at the Indemnitee’s sole cost and expense) to participate in such settlement or defense through counsel chosen by the Indemnitee. 
 (ii) The Indemnitee agrees to preserve and provide access to all evidence in its possession or control that may be useful in defending against a Claim and to provide reasonable cooperation in the defense thereof or in
the prosecution of any action against a third party in connection therewith at the Indemnitor’s expense. The Indemnitor’s defense of any Claim or demand shall not constitute an admission or concession of liability therefor or otherwise
operate in derogation of any rights the Indemnitor may have against the Indemnitee or any third party. So long as the Indemnitor is reasonably contesting any such Claim in good faith, the Indemnitee shall not pay or settle any such Claim.

 (iii) If the Indemnitor elects not to undertake the defense of the Claim, the Indemnitee shall have the right to assume the
defense of the Claim through counsel of its own choosing and contest, settle or compromise the Claim in the exercise of its exclusive discretion at the expense of the Indemnitor. All reasonable expenses incurred by the Indemnitee pursuant to this
Section 14.3(iii) shall be reimbursed by the Indemnitor within twenty (20) days of receipt of competent written evidence of such expenses. 
 15.
INCIDENTAL AND CONSEQUENTIAL DAMAGES. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE TO THE OTHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY
INCIDENTAL OR CONSEQUENTIAL DAMAGES WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT. THE LIMITATIONS IN THIS SECTION 15 SHALL NOT APPLY TO OBLIGATIONS OF EITHER PARTY UNDER SECTION 14 (INDEMNIFICATION), BREACHES BY EITHER PARTY OF SECTION 10
(CONFIDENTIALITY), INTENTIONAL MISCONDUCT OR FRAUD OF EITHER PARTY OR TO INTENTIONAL ACTIONS OF LICENSEE BEYOND THE SCOPE OF THE LICENSE GRANT HEREUNDER. FURTHER, THIS SECTION DOES NOT LIMIT LIABILITY FOR BODILY INJURY OF A PERSON. 
 16. LIMITATION OF OBLIGATIONS AND LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY FOR COST OF PROCUREMENT OF SUBSTITUTE GOODS, SERVICES, 

  

	***	Confidential treatment requested 

 15 

 
TECHNOLOGY OR RIGHTS. FURTHER, EXCEPT FOR OBLIGATIONS OF EITHER PARTY UNDER SECTION 14 (INDEMNIFICATION), WHICH ARE NOT LIMITED BY THIS SENTENCE, NEITHER
PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY AMOUNTS AGGREGATING IN EXCESS OF US-$*** (*** US DOLLARS). THIS SECTION DOES NOT LIMIT LIABILITY FOR INTENTIONAL MISCONDUCT, FRAUD OR BODILY INJURY OF A PERSON.

 17. Insurance. 
 17.1 During the term
of this Agreement, each party shall maintain commercial general liability insurance in amounts not less than $*** per occurrence and $*** annual aggregate. Such commercial general liability insurance shall include but not be limited to contractual
and product liability coverage. The general liability insurance shall include worldwide coverage. The liability policies required under this Section 17 shall be written as primary and non-contributing to not in excess of any coverage the other
party may choose to maintain. The minimum amounts of insurance coverage required under this Section 17 shall not be construed to create a limit of a party’s liability hereunder. 
 17.2 Each party shall provide the other party with written evidence of such insurance at any time during the term of this Agreement promptly upon the
request of the other party. Each party shall provide the other party with written notice at least 15 days prior to any cancellation, non-renewal or material change in such insurance. If a party does not obtain replacement insurance providing
comparable coverage prior to the expiration of such 15-day period, the other party shall have the right to terminate this Agreement effective at the end of such 15-day period without any additional waiting periods. 
 17.3 Each party shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during the period that
any Products and/or Combinations are commercially marketed, distributed or sold under this Agreement. 
 18. Export Control. Licensee shall comply
with and shall, at Licensor’s request, demonstrate such compliance with, the U.S. Foreign Corrupt Practices Act and all applicable export laws, restrictions, and regulations of any U.S. or foreign agency or authority, and shall obtain, and bear
all expenses relating to, any necessary licenses and/or exemptions with respect to the export from the U.S. or elsewhere by Licensee or its agents of any Peptide (or any product or material containing, incorporating or based on any Peptide) or any
Technology or other technology or information it obtains or learns pursuant to this Agreement (or any direct product thereof). 
 19. Independent
Contractors. The parties are independent contractors and not partners, joint venturers or otherwise affiliated and neither has any right or authority to bind the other in any way. 
  

	***	Confidential treatment requested 

 16 

 20. Assignment. The rights and obligations of the parties under this Agreement may not be assigned or transferred
(and any attempt to do so will be void), except that: (i) rights to payment of money may be assigned; and (ii) this Agreement and the rights and obligations hereunder may be assigned by a party to an Affiliate or acquiror of all or
substantially all of its assets, business or capital stock. 
 21. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED IN SECTION 13, LICENSOR MAKES NO
WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE
FOREGOING. LICENSEE MAKES NO WARRANTY WITH RESPECT TO ANY IMPROVEMENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER TO BE FURNISHED TO LICENSOR PURSUANT TO SECTION 5 AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
 22. Miscellaneous. 
 22.1 Amendment and Waiver. Except as otherwise expressly provided herein, any provision of this Agreement may be amended and the observance of any
provision of this Agreement may be waived (either generally or any particular instance and either retroactively or prospectively) only with the written consent of the parties. 
 22.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York and the United States without regard
to conflicts of laws provisions thereof and without regard to the United Nations Convention on Contracts for the International Sale of Goods. 
 22.3 Arbitration. Any dispute relating to the validity, performance, construction or interpretation of this Agreement which cannot be resolved amicably between the parties shall be submitted to binding arbitration to be held in New
York, New York in accordance with the Rules of Arbitration of the International Chamber of Commerce. The arbitration and any pre-arbitral proceedings shall be conducted in English and all documents shall be construed from the English versions
thereof. The decision of the arbitrators in any arbitration proceeding between the parties under this Section 22.3 shall be (i) in writing, stating the reasons therefore; (ii) based solely on the terms and conditions of this
Agreement, as interpreted in accordance with the laws of the State New York and the United States, (iii) final and binding upon the parties hereto; and (iv) enforceable in any court of competent jurisdiction. However, in urgent cases each
party shall have the right to seek preliminary and permanent injunctive relief in any court located in New York, New York, or, if such courts lack jurisdiction, in any court of competent jurisdiction. 
  

	***	Confidential treatment requested 

 17 

 22.4 Headings. Headings and captions are for convenience only and are not to be used in the
interpretation of this Agreement. 
 22.5 Notices. All notices, requests, and other communications hereunder shall be in writing. Any
notice, request, or other communication hereunder shall be deemed duly given: (a) when delivered personally to the recipient; (b) 1 business day after being sent to the recipient by reputable overnight courier service (charges prepaid); or
(c) 1 business day after being sent to the recipient by fax, and addressed to the intended recipient as set forth below: 
  

							
	If to Licensee:	  		  	 If to Licensor:
	  	
				
	 Address:
	  	Goldschmidt GmbH	  	 Address:
	  	Helix BioMedix, Inc.
		  	Goldschmidtstrasse 100	  		  	22118 20thAvenue SE
		  	45127 Essen	  		  	Suite 204
		  	Germany	  		  	Bothell, WA 98021
	 Fax:
	  	***	  		  	USA
	 Attn:
	  	Legal Department	  	 Fax:
	  	(425) 806-2999
		  		  	 Attn:
	  	Chief Financial Officer

  

			
		
	 Copy to:
	  	
	Fax:	  	***
	Attn:	  	VP and General Manager Personal Care

 Either party may change the address or other contact information to which notices, requests, and other
communications hereunder are to be delivered by giving the other party notice in the manner set forth herein. 
 22.6 Entire
Agreement. This Agreement supersedes all proposals, oral or written, all negotiations, conversations, or discussions between or among the parties relating to the subject matter of this Agreement and all past dealing or industry custom.

 22.7 Force Majeure. Neither party hereto shall be responsible for any failure to perform its obligations under this Agreement
(other than obligations to pay money or obligations under Section 10 (Confidentiality)) if such failure is caused by acts of God, war, strikes, revolutions, lack or failure of transportation facilities, laws or governmental regulations or other
causes that are beyond the reasonable control of such party. Obligations hereunder, however, shall in no event be excused but shall be suspended only until the cessation of any cause of such failure. In the event that such force majeure should
obstruct performance of this Agreement for more than six (6) months, the parties hereto shall consult with each other to determine whether this Agreement should be modified. The party facing an event of force majeure shall use diligent
commercial efforts in order to remedy that situation as well as to minimize its effects. A case of force majeure shall be notified to the other party within 5 days after its occurrence. 
  

	***	Confidential treatment requested 

 18 

 22.8 Severability. If any provision of this Agreement is held illegal, invalid or unenforceable by
a court of competent jurisdiction or the arbitration tribunal, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. 
 22.9 No Implied License. Each party recognizes that Licensor grants no license, by implication or otherwise, except for the licenses expressly set
forth in this Agreement. 
 22.10 Counterparts. This Agreement may be executed in one or more counterparts (including by means of
facsimile), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 22.11
Basis of Bargain. Each party recognizes and agrees that the warranty disclaimers and liability and remedy limitations in this Agreement are material bargained for bases of this Agreement and that they have been taken into account and
reflected in determining the consideration to be given by each party under this Agreement and in the decision by each party to enter into this Agreement. 
 [Signature page follows] 
  

	***	Confidential treatment requested 

 19 

 The parties have entered into this Agreement as of the date first written above. 
  

									
	LICENSEE:	 		 	LICENSOR:
			
	GOLDSCHMIDT GMBH	 		 	HELIX BIOMEDIX, INC.
					
	By:	 	/s/ Peter Lersch	 		 	By:	 	/s/ David Kirske
	Name:	 	Dr. Peter Lersch	 		 	Name:	 	David Kirske
	Title:	 	Head of R&D Care Ingredients/Biotechnology	 		 	Title:	 	VP and Chief Financial Officer

  

			
	GOLDSCHMIDT GMBH
		
	By:	 	/s/ Astrid Wedler
	Name:	 	Astrid Wedler
	Title:	 	Legal Counsel

 [SIGNATURE PAGE TO LICENSE AGREEMENT] 

 EXHIBIT A 
 PATENT APPLICATIONS 
 (FILING JURISDICTIONS) 
 *** 
  

	***	Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]